Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational study assessing Apabetalone

Next Previous
Trial Profile

A registrational study assessing Apabetalone

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms BETonMACE2

Most Recent Events

  • 12 Jan 2021 According to a Resverlogix Corporation media release, the company will be including hospitalizations for heart failure in the composite primary endpoint in this study in agreement with the US Food and Drug Administration (FDA) following receipt of the Breakthrough Therapy Designation.
  • 29 Jun 2020 New trial record
  • 28 Jun 2020 According to a Resverlogix Corporation media release, Filing of a New Drug Application (NDA) with the FDA is possible following unequivocal efficacy at an interim analysis of BETonMACE2

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top